Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule. As previously disclosed, on January 15, 2026 the Company received a notice from Nasdaq indicating that the closing bid price of the Company’s common stock had been below $1.00 for 30 consecutive business days, and, consequently, the Company was not in compliance with Nasdaq Listing